Top 3 formulary access takeaways for pharma

For the feature in its entirety, click here. 

1. As much as the battle over the prices of hep.-C drugs has generated attention, pharma marketers should be careful about drawing conclusions about its impact on PBM negotiations in other therapeutic categories. 

2. Research collaborations—like the ones between Anthem, its HealthCore research arm and companies like AstraZeneca, Boehringer Ingelheim and Eli Lilly—offer a new path for the parties to work together for everyone’s collective benefit. 

3. The next possible pricing battlegrounds for pharma companies and PBMs could be cholesterol or cancer drugs.